Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TU2670 in moderate to severe endometriosis-associated pain
2020-000090-25Phase 2Completed
- Sponsor
- TiumBio Co., Ltd.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in endometriosis comparing TU2670 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in mean dysmenorrhea score. Started Jun 2021; status: completed.
02
Drugs
merigolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on 2020-000090-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000090-25.